285984-25-0Relevant articles and documents
MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF
-
Page/Page column 76, (2019/12/25)
Compounds that inhibit mitogen-activated protein kinases (MAPKs) are disclosed. Some inhibitor compounds specifically target a single MAPK such as MAPK13, while others target multiple MAPKs such as MAPK13 and MAPK12. The compounds can be used therapeutica
Substituted benzo pyrazole diaryl urea compound, its preparation method and medical use thereof (by machine translation)
-
Paragraph 0075; 0076; 0115, (2017/04/25)
The invention substituted benzo pyrazole diaryl urea compound, its preparation method and medical use thereof relates to a compound of formula I, or an isomer, a pharmaceutically acceptable salt and solvates; the invention also relates to the general formula I compound or its isomer, pharmaceutically acceptable salt and solvates, and a pharmaceutically acceptable carrier, excipient or diluent composition; the invention also relates to the compounds of the formula I, or an isomer, a pharmaceutically acceptable salt and solvates, used for overcoming the inflammation, inflammation-related diseases, tumor and asphyxiating gas or irritant gas caused by the use of acute lung injury; in particular with the P38 MAPK pathway-related diseases or symptoms in use. (by machine translation)
Substituted benzothiazole diaryl urea compounds, and preparation method and medical application thereof
-
Paragraph 0076, (2017/08/28)
The invention relates to compounds as shown in a general formula I which is described in the specification, or isomers, medicinal salts and solvates thereof. The invention also relates to a composition containing the compounds as shown in the general formula I or the isomers, medicinal salts and solvates thereof, and a pharmaceutically acceptable carrier, an excipient or a diluent. The invention also relates to application of the compounds as shown in the general formula I or the isomers, medicinal salts and solvates thereof to treatment of inflammations, inflammation-related diseases, tumors and acute lung injury or symptoms caused by suffocating gas or irritant gas, especially to diseases or symptoms related to a P38 MAPK pathway.